Warren Buffett
Berkshire Hathaway
Warren Buffett Royalty PharmaPlc stake
total: 135
Berkshire Hathaway RPRX trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 2
- Held since:
- 2021 Q3
- Held for:
- 3 quarters
- Latest activity:
- 2022 Q2
According to 2026 Q2 report, Warren Buffett doesn't hold any Royalty PharmaPlc (RPRX) shares. To date, the estimated cost basis is nearly $36.14 for "buy" trades and estimated average "sell" price is $39.27. Berkshire Hathaway first purchased RPRX in 2021 Q3, initially acquiring about 13.15M shares. Since the initial investment in Royalty PharmaPlc (RPRX), Berkshire Hathaway has made 3 more transactions.
When did Warren Buffett sell Royalty PharmaPlc (RPRX)?
Warren Buffett sold off the entire Royalty PharmaPlc (RPRX) position in 2022 Q2.
When did Warren Buffett buy Royalty PharmaPlc (RPRX)?
Warren Buffett first invested in Royalty PharmaPlc (RPRX) in 2021 Q3 at the reported quarter-end price of $36.14 per share.
What's the cost basis of Berkshire Hathaway's RPRX stake?
The estimated cost basis for Royalty PharmaPlc (RPRX) stake is around $36.14 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $36.14
- Weighted AVG sell price:
- $39.26
Warren Buffett's historical trades in Royalty PharmaPlc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$38.96
|
|
-100% (-1,496,372)
|
-0.02%
|
|
2022 Q1
|
0.02%
|
1,496,372
|
$38.96
|
$58,299,000
|
-82.70% (-7,151,896)
|
-0.08%
|
|
2021 Q4
|
0.10%
|
8,648,268
|
$39.85
|
$344,633,000
|
-34.21% (-4,497,634)
|
-0.06%
|
|
2021 Q3
|
0.16%
|
13,145,902
|
$36.14
|
$475,093,000
|
new
|
+0.16%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.